Comparative pharmacokinetic study of two lyophilized orally disintegrating tablets formulations of vinpocetine in human volunteers

International Journal of Drug Delivery

Volumn 5, Issue 2, 2013, Pages 167-176

  Kharshoum, Rasha M ^a   Sanad, Rania A ^b   Ali, Ahmed M Abdelhaleem ^a  

^a Beni Suef University   (Egypt)

^b NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

Author keywords

Bioavailability; Inclusion complex; Lyophilization; Orodispersible tablets; Solid dispersion; Vinpocetine

Indexed keywords

CYCLODEXTRIN; MACROGOL 4000; VINPOCETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG SOLUBILITY; FLOW RATE; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INFRARED SPECTROSCOPY; MALE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET COMPRESSION; TABLET DISINTEGRATION; TABLET FORMULATION; TABLET FRIABILITY;

EID: 84904111203     PISSN: None     EISSN: 09750215     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. Pharmacol. Eur. J. Clin., 1999(55): p. 349-352.
2. Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchernov DV. Vinpocetine treatment in acute ischaemic stoke: a pilot single-blind randomized. clinical trial. Eur. J., 2001(8): p. 81-85.
3. Chen JCJ, Tao W, Mei N, Cao S, Jiang X. Determination of apovincaminic acid in human plasma by high-performance liquid chromatography using solid-phase extraction and ultraviolet detection. J Chromatogr B., 2006. 830: p. 201-206.
4. Kiss B, Karpati E. Mechanism of action of vinpocetine. Acta. Pharm. Hung., 1996(66): p. 213-214.
5. Del Valle, E.M.M., Cyclodextrins and their uses. a review. Process Biochemistry, 2004. 39: p. 1033-1046.
6. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech, Article 34, 2005. 6(2): p. E329-E357.
7. Polgar M, Vereczkey, Nyary I. Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion. J. Pharm. Biomed. Anal., 1985. 3: p. 131-139.
8. Gupta, S, Srivastav S, Vajpai M. Solid dispersion technique for improving solubility of some poorly soluble drugs. Journal of Pharmacy Research, 2012. 3(4): p. 574-1586.
9. Ali AA, Ali AMAH. Optimization of propranolol HCl release kinetics from press coated sustained release tablets. Pharmaceutical Development and Technology, 2012(00): p. 1-9.
10. Rudnic E, Schwartz JB, Oral Solid Dosage forms In: Remington's Pharmaceutical Sciences. 18th edition,1990, Mack publishing Company. Easton, Pennsylvania, USA. p. 633-1665.
11. The Biritich Pharmacopoia. 2001: Vol. I and Il. London: The statiory office, p.705-706,1810-1812
12. Kottke MK, Rudnic EM. Tablet Dosage Forms, in Modern Pharmaceutics, G.S. Banker, and Rhodes, C.T., Editor. 2002, Marcel Dekker Inc.: New York. p. 437-511.
13. Alderborn G. Tablets and compaction, in Pharmaceutics The Science of Dosage Form Design, M.E. Aulton, Editor. 2002, Churchill Livingstone: Edinburgh. p. 397-439.
14. Abd Elbary A, Foda N, El-Gazayerly, O, El Khatib M. Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application. 2002. Anal. Lett. (35): p. 1041-1054.
15. Botha SA, Lötter AP. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations, Drug. Dev. Ind. Pharm, 1990. 16(4): p. 673.
16. Murrell W. Nitroglycerin as a remedy for angina pectoris. Vol.151. 1879: Lancet.
17. Liu L, Zhu S. Preparation and characterization of inclusion complexes of prazosin hydrochloride with betacyclodextrin and hydroxypropyl-betacyclodextrin. J Pharm Biomed Anal, 2006. 40(1): p. 122-7.
18. Ahuja N, Katare O P, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using watersoluble carriers. Eur. J. Pharm. Biopharm, 2007. 65(1): p. 26-38.
19. Ribeiro, LSS. Ferreira DC, Veiga FJB. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextirn and its sulfobytyl ether derivative in solution and solid state. Eur. J. Pharm. Sci., 2003. 20(3): p. 253-266.
20. Jun SW, Kim MS, Kim JS, Park HJ, Lee S, Woo JS, Hwang SJ. Preparation and characterization of simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm, 2007. 66(3): p. 413-421.
21. Fernandes CM, Teresa VM, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipinecyclodextrins inclusion compounds. Eur. J. Pharm. Sci., 2002. 15(1): p. 79-88.
22. Ficarra R. et al. Study of the inclusion complex of atenolol with betacyclodextrins. J Pharm Biomed Anal, 2000. 23(1): p. 231-6.
23. Conine JW, Pikal MJ. Pharmacutical Dosage FormsTablets, ed. H.A. Liberman, Lachman, L., Schwartz J.B. Vol. 1. 1989: New York: Marcel Dekker. p.329-340.
24. Farzana SB, Ibrahim S. Khattab, Lyophilized gliclazidepoloxamer solid dispersions for enhancement of invitrodissolution and invivo bioavailability. International Journal of Pharmacy and Pharmaceutical Sciences, 2011. 3(2).
25. Ribeiroa L, Ferreirab DC, Veiga FJ. In vitro controlled release of vinpocetinecyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. J Control Rel, 2005. 103: p. 325-339.
26. Jacobsen J, Christrup L, Jensen N. Medicated chewing gum: pros and cons Am J Drug Delivery, 2004. 2(2): p. 75-88.
27. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol, 1998. 50(4): p. 375-382.
28. Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Exp. Opinion Drug Del, 2005. 2: p. 335-351.
29. Senel S, Hincal AA. Drug permeation enhancement via. buccal route: Possibilities and limitations. J. Control. Rel., 2001. 72: p. 133-144.
30. Vandecruys R, Peeters J, Verreck G, Brewster ME., Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int. J. Pharm., 2007. 342(1-2): p. 168-175.
31. Yoo SD, Yoon BM, Lee HS, Lee KC. Increased bioavailability of clomipramine after sublingual administration in rats. J. Pharm. Sci., 1999. 88(11): p. 1119-1121.
32. Udata C, Patel J, Pal D, Hejchman E, Cushman M, Mitra AK. Enhanced transport of a novel anti-HIV agent--cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers. Int. J. Pharm., 2003. 250(1): p. 157-168.
33. Martins PS, Ochoa R, Pimenta AM, Ferreira LA, Melo AL, da Silva JB, Sinisterra RD, Demicheli C, Frézard F. Mode of action of beta-cyclodextrin as an absorption enhancer of the watersoluble drug meglumine antimoniate. Int. J. Pharm., 2006. 325(1-2): p. 39-47.